Unraveling Origins: Direct-to-Consumer Genetic Testing Market Forecasted to Reach US$ 4,843.4 Million by 2033

The global Direct-To-Consumer Genetic Testing Market was worth US$ 1,485.1 million in 2022 and is expected to be worth US$ 1645.5 million in 2023. According to Future Market Insights, the smart agriculture solution market will grow at a CAGR of 11.40% between 2023 and 2033, totaling around US$ 4,843.4 million by 2033.

Increased income levels in developing countries are expected to drive the growth of the direct-to-consumer (DTC) genetic testing market, while an increase in the cost of DTC genetic testing is expected to drive the growth of the DTC genetic testing market over the forecast period.

Accelerate Your Journey to Excellence with Unmatched Efficiency! Claim Your Sample Now :
https://www.futuremarketinsights.com/reports/sample/rep-gb-15137

Key Takeaways from this Market:

• The global direct-to-consumer genetic testing market is expected to grow at a CAGR of 11.2% from 2022 to 2032 and is likely to reach US$ 4.0 Billion in 2032.
• The global direct-to-consumer genetic testing (DTC-GT) market grew at a CAGR of 9.8% between 2017 and 2022.
• Direct-to-consumer genetic testing (DTC-GT) market grew at a CAGR of 15.6% and held about US$ 8.0 Billion of the global genetic testing market in 2021.
• North America holds a major portion of the market with a value share of 48.2%.
• The United States holds a direct-to-consumer genetic testing market share of about 42.9%.
• Japan is said to hold an important part of the market with a value share of 6.3%.
• China market is said to grow at a CAGR of 12.7% in East Asia.
• India uses genetic screening services growing at a CAGR of 15.3%.
• The Australian market is expected to expand at a CAGR of 8.9%.
• Germany is set to exhibit a CAGR of nearly 7.1% in Europe where it holds 32.7% of the market share.
• United Kingdom is likely to grow at a CAGR of 11.8%.
• Ancestry tests segment exhibited high growth at a CAGR of 10.9%, with a projected share of about 38.2% in the global market in the same year.
• The single nucleotide polymorphism chips segment held a market share of around 64.5% and is expected to showcase gradual growth over the forecast period.
• The saliva segment held a direct-to-consumer genetic testing market share of 67.0%.
• The retail sales segment held the highest direct-to-consumer genetic testing market share of nearly 79.5%.

“Usage of genetic marketers for affirming the existence of kinship relationships acts as one of the major opportunities in direct-to-consumer genetic testing manufacturers,” – comments an Analyst at Future Market Insights (FMI).

Unleash Your Investment Potential: Exclusive Insights and Expert Analysis Await in Our Comprehensive Analyst Report :
https://www.futuremarketinsights.com/ask-question/rep-gb-15137

Competitive Landscape:

Some of the prominent players in the global market are:

• 23andMe
• Ancestry DNA
• Color Genomics, Inc.
• Genetic Technology (EasyDNA)
• Full Genomes Corporation, Inc.
• Helix OpCo LLC
• IDENTIGENE, LLC/ DNA Diagnostics Center
• Living DNA Ltd
• MyHeritage Ltd
• Prenetics Limited
• Family Tree DNA
• Interleukin Genetics/orig3n
• Counsyl/Myriad Genetics, Inc.
• Veritas Genetics
• Fulgent Genomics

Some of the recent industry developments in the global direct-to-consumer genetic testing market are:

• In May 2023, 23andMe offers a trove of information about your genetics and deeper ancestry where this top DNA testing service also provides checks for genetic health risks and your carrier status for many conditions.

More Valuable Insights Available:

Future Market Insights offers an unbiased analysis of the direct-to-consumer genetic testing market providing historical data for 2017 to 2022 and forecast statistics from 2023 to 2033.

To understand opportunities in the direct-to-consumer genetic testing market is segmented based on major by By Product: (Pharmacogenetics Tests, Carrier Screening Tests, Genetic Health Risk (GHR) Tests, Cancer Predisposition Tests, Low-Risk General Wellness Tests, Ancestry Tests), By Technology: (Single Nucleotide Polymorphism Chip, Whole Genome Sequencing), By Sample: (Saliva, Urine, Blood), By Sales Channel: [(Institutional Sales- Hospitals, Specialty Clinics, Diagnostic Laboratories, Others), (Retail Sales- Retail Pharmacies, Online Sales)], By Region: (North America, Latin America, Europe, South Asia, East Asia, Oceania, The Middle East and Africa)

Market Outlook by Categorization:

By Product:

• Pharmacogenetics Tests
• Carrier Screening Tests
• Genetic Health Risk (GHR) Tests
• Cancer Predisposition Tests
• Low-Risk General Wellness Tests
• Ancestry Tests

By Technology:

• Single Nucleotide Polymorphism Chip
• Whole Genome Sequencing

By Sample:

• Saliva
• Urine
• Blood

By Sales Channel:

• Institutional Sales
  • Hospitals
  • Specialty Clinics
  • Diagnostic Laboratories
  • Others
• Retail Sales
  • Retail Pharmacies
  • Online Sales

By Region:

• North America
• Latin America
• Western Europe
• Eastern Europe
• South Asia & Pacific
• East Asia
• Middle East and Africa

Unlock Exclusive Market Segments Insights: Buy Now :
https://www.futuremarketinsights.com/checkout/15137

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:          

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube